The announcement details the initiation of a Phase III clinical trial for SYS6010, a drug developed by its subsidiary, Giant Biologics. The trial aims to evaluate the safety and efficacy of SYS6010 combined with PD-1 inhibitor in treating specific types of non-small cell lung cancer. The company acknowledges the high investment and risks associated with drug development.
Summary generated by AI · Always verify with source document
Stock Code: 300765
Stock Abbreviation: CStone Pharma
Announcement No.: 2026-060
CStone Pharma Co., Ltd.
Announcement on the Initiation of Phase III Clinical Trial of SYS6010 by Subsidiary
The Company and all members of the Board of Directors guarantee the truthfulness, accuracy, and completeness of the information disclosed, and that there are no false records, misleading statements, or material omissions.
Sign in to read the full translation
Free accounts get 10 full releases per month. Pro subscribers get unlimited access.